Mina Allahverdi, S. Angaji, B. Beikzadeh, Raheleh Roudi
{"title":"Association Study between rs10486567, rs13149290, rs1545985 and rs6983267 with Incidence of Prostate Adenocarcinoma Among Iranians","authors":"Mina Allahverdi, S. Angaji, B. Beikzadeh, Raheleh Roudi","doi":"10.2174/0118756921287724240628080642","DOIUrl":"https://doi.org/10.2174/0118756921287724240628080642","url":null,"abstract":"\u0000\u0000Prostate cancer is the second most frequent malignancy after lung cancer\u0000among men, accounting for 7% of new cancers diagnosed around the world (15% in developed regions).\u0000This disease has become more prevalent in Iran over the past few decades, moving up the\u0000rankings from 13th in 1986 to 4th in 2005 and finally reaching third place in a recent study in 2016.\u0000The purpose of this study is to investigate the association of rs10486567, rs13149290, rs6983267,\u0000and rs1545985 with prostate cancer predisposition in the Iranian population. Due to the genetic heterogeneity,\u0000each of the SNP should be studied separately in various communities.\u0000\u0000\u0000\u0000This study was conducted as a case-control study on 200 patients referred\u0000to Hashminejad Hospital in Tehran. 103 men with prostate adenocarcinoma were selected as case,\u0000and 97 men with benign prostatic hyperplasia (BPH) were selected as control. In this research, according\u0000to FAVORGENE-Taiwan extraction kit instructions, genomic DNA was extracted from\u0000peripheral blood lymphocytesTetra-primer ARMS-PCR method was used for SNP genotyping.\u0000\u0000\u0000\u0000The significance level at the first stage was p-value≤0.4. rs10486567 (p-value = 0.802) and\u0000rs6983267 (p-value = 0.684). Based on the additive and multiplicative genetic model, no association\u0000of these polymorphisms with prostate adenocarcinoma was observed. As a result, rs10486567\u0000and rs6983267 were removed at this stage. rs13149290 (p-value=0.4) and rs1545985 (p-value=0.4)\u0000at this stage were selected for the next stage. At the second stage rs13149290 (p-value=0.043)\u0000showed a significant difference in the comparison between the two groups, but this difference was\u0000not observed in relation to rs1545985 (p-value=0.392) rs1545985 was not associated with prostate\u0000adenocarcinoma in the additive genetic model. According to P=0.013 and OR (95% CI) =3.837\u0000(1.306-11.268), rs13149290 polymorphism is associated with prostate adenocarcinoma in the additive\u0000genetic model (TT vs CC).\u0000\u0000\u0000\u0000As a result of this study, it was observed that rs13149290 is associated with prostate\u0000cancer in the Iranian population. Also this polymorphism is associated with Gleason score=7 and\u0000PSA ≤4. Prostate cancer as an exposure effect is heterogeneous between different PSA levels. It is\u0000suggested that this polymorphism be investigated in a larger population and in each ethnic group\u0000separately.\u0000","PeriodicalId":11056,"journal":{"name":"Current Pharmacogenomics and Personalized Medicine","volume":" 16","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141678232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Clinical Trial Participant's Perspectives on Genetic Research Data Re-uses for Future Research","authors":"R. Devarinti, M. S. Ganachari","doi":"10.2174/0118756921305151240503075928","DOIUrl":"https://doi.org/10.2174/0118756921305151240503075928","url":null,"abstract":"\u0000\u0000Clinical trial participants play a crucial role in advancing medical\u0000research, and the data generated from their participation can indeed be invaluable for\u0000future studies. However, the reuse of genetic or clinical research data comes with ethical\u0000challenges that need careful consideration. Here are some of the key ethical issues associated\u0000with the re-use of such data: Reusing data without clear informed consent raises issues\u0000of autonomy and respect for individuals' choices.\u0000\u0000\u0000\u0000The main aim of this study is to assess the understanding of individuals involved\u0000in clinical trials regarding the sharing of genetic research information. Moreover,\u0000it seeks to explore the ethical issues and benefits linked with the use of genetic research\u0000data for future research initiatives.\u0000\u0000\u0000\u0000A cross-sectional observational study was applied to assess\u0000Knowledge Attitude Practices of clinical trial participants on reuse of genetic research data.\u0000\u0000\u0000\u0000The majority 70% of clinical trial participants were unsure about the difficulties\u0000that may arise in future regarding the re-use of genomic data, with concerns about confidentiality\u0000being the most common.\u0000\u0000\u0000\u0000The present study prioritized the involvement of clinical trial participants\u0000due to their critical role in both genetic and clinical research endeavors. There is a lack of\u0000awareness and understanding regarding the re-use of genetic sample data and ethical issues\u0000among the trial participants. Researchers must take measures to de-identify or anonymize\u0000data to protect participants. There is a clear need for comprehensive awareness\u0000programs and guidelines aimed at all clinical trial stakeholders. These initiatives would\u0000ensure that researchers, participants, and other involved parties are well-informed and adhere\u0000to ethical standards when utilizing genetic data for subsequent research endeavors.\u0000","PeriodicalId":11056,"journal":{"name":"Current Pharmacogenomics and Personalized Medicine","volume":"120 30","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141126681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Exosome and Other Extracellular Vesicles in Gene Therapy and\u0000Personalized Care","authors":"Neha Minocha, Satish Sardana","doi":"10.2174/0118756921285480240118051820","DOIUrl":"https://doi.org/10.2174/0118756921285480240118051820","url":null,"abstract":"\u0000\u0000Exosomes and other extracellular vesicles (EVs) have emerged as versatile\u0000agents facilitating cell-to-cell communication, assuming pivotal roles in both physiological and pathological contexts. This manuscript presents an extensive overview of the existing knowledge concerning the utilization of exosomes and EVs in gene therapy and\u0000personalized healthcare. It delves into their inherent capacity for transferring genetic material, their limited immunogenicity, and their potential for precise and targeted delivery.\u0000Furthermore, the paper investigates the ever-evolving domain of biomarker discovery,\u0000where exosomes and EVs hold substantial promise for the early detection of diseases and\u0000the monitoring of treatment responses. As ongoing research advances, the manuscript explores the potential for refining protocols related to standardization and quality control,\u0000along with the optimization of scalable manufacturing methods. Additionally, the manuscript sheds light on the burgeoning potential for individualized treatments driven by genomic profiling. By examining these facets, we foresee that exosomes and EVs will play\u0000a pioneering role in ushering in a new era of precision medicine, offering safer, more efficacious, and highly customized therapeutic interventions across a spectrum of medical\u0000conditions.\u0000","PeriodicalId":11056,"journal":{"name":"Current Pharmacogenomics and Personalized Medicine","volume":"46 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139608419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}